Jeffrey N.  Simmons net worth and biography

Jeffrey Simmons Biography and Net Worth

Jeffrey N. Simmons is the President, Chief Executive Officer and Director of the Company. Mr. Simmons as served as Elanco’s President and Chief Executive Officer and as a member of the Board since July 2018. Mr. Simmons served as the President of the Elanco Animal Health division of Lilly and Senior Vice President of Lilly from 2008 until September 2018. Prior to 2008, Mr. Simmons held various leadership roles for Elanco, including District Sales Manager, International Marketing Manager, Country Director for Brazil, Area Director for Western Europe and Executive Director for U.S. and Global Research & Development. Mr. Simmons’ experience described above, including his knowledge of Elanco and the animal health industry and his business and management experience, provides him with the qualifications and skills to serve as a director on Elanco’s Board.

What is Jeffrey N. Simmons' net worth?

The estimated net worth of Jeffrey N. Simmons is at least $111.81 million as of August 12th, 2024. Mr. Simmons owns 145,000 shares of Eli Lilly and Company stock worth more than $111,809,500 as of December 18th. This net worth approximation does not reflect any other assets that Mr. Simmons may own. Additionally, Mr. Simmons receives a salary of $1,730,000.00 as SVP at Eli Lilly and Company. Learn More about Jeffrey N. Simmons' net worth.

How old is Jeffrey N. Simmons?

Mr. Simmons is currently 57 years old. There are 7 older executives and no younger executives at Eli Lilly and Company. Learn More on Jeffrey N. Simmons' age.

What is Jeffrey N. Simmons' salary?

As the SVP of Eli Lilly and Company, Mr. Simmons earns $1,730,000.00 per year. There are 4 executives that earn more than Mr. Simmons. The highest earning executive at Eli Lilly and Company is Mr. David A. Ricks, Chairman, CEO & President, who commands a salary of $6,290,000.00 per year. Learn More on Jeffrey N. Simmons' salary.

How do I contact Jeffrey N. Simmons?

The corporate mailing address for Mr. Simmons and other Eli Lilly and Company executives is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. Eli Lilly and Company can also be reached via phone at (317) 276-2000 and via email at [email protected]. Learn More on Jeffrey N. Simmons' contact information.

Has Jeffrey N. Simmons been buying or selling shares of Eli Lilly and Company?

Jeffrey N. Simmons has not been actively trading shares of Eli Lilly and Company over the course of the past ninety days. Most recently, Jeffrey N. Simmons sold 9,027 shares of the business's stock in a transaction on Thursday, May 3rd. The shares were sold at an average price of $78.50, for a transaction totalling $708,619.50. Learn More on Jeffrey N. Simmons' trading history.

Who are Eli Lilly and Company's active insiders?

Eli Lilly and Company's insider roster includes Anat Ashkenazi (Sr. VP & CFO ), Melissa Barnes (SVP), Enrique Conterno (SVP), Stephen Fry (SVP), Michael Harrington (VP), Susan Mahony (SVP), Johna Norton (EVP), Myles O'Neill (SVP), Derica Rice (EVP), David Ricks (CEO), Marschall Runge (Director), Aarti Shah (SVP), Christi Shaw (SVP), Jeffrey Simmons (SVP), Daniel Skovronsky (SVP), Joshua Smiley (CFO), Jackson Tai (Director), Jacob Van Naarden (Sr. VP), Alonzo Weems (EVP), Anne White (SVP), Ilya Yuffa (SVP), Donald Zakrowski (CAO), and Alfonso Zulueta (SVP). Learn More on Eli Lilly and Company's active insiders.

Are insiders buying or selling shares of Eli Lilly and Company?

In the last year, insiders at the sold shares 26 times. They sold a total of 1,410,659 shares worth more than $1,192,819,015.29. The most recent insider tranaction occured on November, 8th when CAO Donald A Zakrowski sold 900 shares worth more than $723,042.00. Insiders at Eli Lilly and Company own 0.1% of the company. Learn More about insider trades at Eli Lilly and Company.

Information on this page was last updated on 11/8/2024.

Jeffrey N. Simmons Insider Trading History at Eli Lilly and Company

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/3/2018Sell9,027$78.50$708,619.50View SEC Filing Icon  
2/5/2018Sell9,625$81.12$780,780.00152,120View SEC Filing Icon  
12/11/2017Sell12,500$86.46$1,080,750.00124,522View SEC Filing Icon  
5/29/2015Sell20,000$78.08$1,561,600.00View SEC Filing Icon  
5/10/2013Sell10,000$54.49$544,900.00View SEC Filing Icon  
See Full Table

Jeffrey N. Simmons Buying and Selling Activity at Eli Lilly and Company

This chart shows Jeffrey N Simmons's buying and selling at Eli Lilly and Company by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Eli Lilly and Company Company Overview

Eli Lilly and Company logo
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Read More

Today's Range

Now: $771.10
Low: $768.00
High: $779.00

50 Day Range

MA: $828.39
Low: $727.57
High: $932.06

2 Week Range

Now: $771.10
Low: $567.02
High: $972.53

Volume

1,768,540 shs

Average Volume

3,202,832 shs

Market Capitalization

$732.02 billion

P/E Ratio

83.36

Dividend Yield

0.66%

Beta

0.41